Carcinoma of the Ovary

Heintz, A. Peter M.; Odicino, Franco; Maisonneuve, Patrick; Quinn, Michael; Benedet, J.L.; Creasman, William T.; Ngan, Hextan Y.S.; Pecorelli, S.; Beller, U.

doi:10.1016/s0020-7292(06)60033-7

Cited by 991 publications

(384 citation statements)

References 0 publications

Supporting

Mentioning

369

Contrasting

Unclassified

Order By: Relevance

“…Histopathology, tumor grade, and disease stage, as defined by the International Federation of Gynecology and Obstetrics, were determined by an independent pathologist who reviewed and graded the tumor samples. 7 Tissue selection criteria for this study were based on serous histopathology from chemotherapy-naive patients, and all samples were collected between 1993 and 2003. Clinical data were extracted from the Systè me d'Archivage des Donne´es en Oncologie, which includes entries on tumor grade and stage; treatment and clinical outcomes, such as the progression-free interval, as defined according to the Response Evaluation Criteria in Solid Tumors 18 ; and survival.…”

Section: Patients and Tissue Specimensmentioning

confidence: 99%

“…The volume and extent of tumor spread define the clinical stage, varying from I to IV, with stage I limited to 1 or both ovaries, stage II associated with pelvic extension, stage III spreading into the abdominal cavity, and stage IV presenting with distant metastases. 6,7 After surgical removal of the tumor mass, patients with EOC usually receive a first line of platinum-based combined chemotherapy (for review, see Agarway and Kaye 8 ). However, even if 80% of patients respond initially to treatment, most patients have recurrent disease and develop treatment resistance, with different latencies indicating the need for a better understanding of the disease and the identification of new therapeutic targets or treatment modalities.…”

mentioning

confidence: 99%

See 1 more Smart Citation

An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer

Ouellet

Page

Madore

et al. 2007

Cancer

View full text Add to dashboard Cite

Protein‐imprinted soft‐gel composite microspheres with magnetic susceptibility (MS‐PIGMs) were prepared by inverse suspension polymerization using Fe3O4 particles as magnetically susceptible component and bovine serum albumin and lysozyme (Lyz) as templates, respectively. The average content of magnetically susceptible component (Fe3O4) inside MS‐PIGMs was determined using thermogravimetric analyzer, and the magnetic characteristics of MS‐PIGMs were measured by vibrating sample magnetometer. The results showed that the resulting MS‐PIGMs had a certain magnetic response to external magnetic fields, and their average content of Fe3O4 was 2.08%. Their recognition specificity was investigated using BSA and Lyz as both templates and control molecules and characterized by high‐performance liquid chromatography, and the mechanism of imprinting and recognition was analyzed. It was shown that the resulting BSA imprinted soft‐gel composite microspheres with magnetic susceptibility (BSA‐PIGMs) and Lyz imprinted soft‐gel composite microspheres with magnetic susceptibility (Lyz‐PIGMs). All exhibited good recognition selectivity for their templates, and the relative separation factor (β) was 4.75 and 5.88, respectively. The recognition selectivity of MS‐PIGMs to their templates depended mainly on the synergic action of a large quantity of hydrogen binding being caused by complementation and very close contact of outer surface of proteins with inner surface of “imprinting cavities.” © 2005 Wiley Periodicals, Inc. J Appl Polym Sci, 2006

show abstract

Section: Patients and Tissue Specimensmentioning

confidence: 99%

mentioning

confidence: 99%

An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer

Ouellet

Page

Madore

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…It constitutes 60% of the malignant tumors of the ovary and is the leading cause of death from gynecologic malignancies. 1 Despite the clinical significance and extensive research, the pathogenesis of this tumor is still a matter of debate. The purported tissue origins include the ovarian surface epithelium, fallopian tube, and secondary Mü llerian system, with the surface epithelial origin as the dominant theory in this field.…”

mentioning

confidence: 99%

Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

et al. 2007

View full text Add to dashboard Cite

PAX2 is a urogenital developmental transcription factor expressed in the Wolffian ducts, developing kidneys, and Mü llerian ducts during embryonic stage. Its function in renal development is well documented and its clinical application in the diagnosis of lesions of renal origin has been reported recently. However, information on its role in the Mü llerian-derived genital tract is sparse. In this study, we investigated the expression of PAX2 in human female genital tract using immunohistochemistry. We demonstrated that PAX2 was expressed specifically in the epithelial cells of fallopian tube, endometrial and endocervical glands, but not in the stromal tissues in these areas. PAX2 was detected in secondary Mü llerian structures in the ovary, such as endometriotic and endosalpingiotic glands and rete ovarii, but not in ovarian surface epithelium, surface epithelium-derived inclusion cysts, stroma, or sex-cord-derived structures such as follicles, oocytes, and corpus luteum. In addition, PAX2 was detected in 67% of ovarian papillary serous carcinomas (N ¼ 36) but rarely in peritoneal malignant mesotheliomas, with two exceptions (N ¼ 54). Interestingly, the two PAX2-positive 'peritoneal malignant mesotheliomas' were from female patients and were positive for estrogen receptor. The significance of expression of PAX2 and estrogen receptor in these cases is under investigation. Taken together, we suggest that PAX2 is a novel Mü llerian-specific epithelial marker when used in proper clinical settings. Identification of PAX2 in the majority of papillary serous carcinomas of the ovary but not in the ovarian surface epithelium or epithelium-derived inclusion cysts suggests that this malignant epithelial tumor may be directly derived from the primary or secondary Mü llerian epithelium in or surrounding the ovary, rather than from the surface epithelium or its derivatives.

show abstract

“…In 2007, an estimated 22 430 new epithelial ovarian cancers were diagnosed in the United States and approximately one-third had FIGO (International Federation of Obstetrics and Gynecology) stage I and II disease with a survival rate ranging from 70 to 90% (Heintz et al, 2006;Jemal et al, 2006). Although the survival of early-stage disease is significantly higher than those with advanced cancers, approximately 20 -30% of patients with early-stage cancers will succumb to their disease (Nguyen et al, 1993;Hoskins et al, 1994;Kosary, 1994;Averette et al, 1995;McGuire et al, 1996;Heintz et al, 2006).…”

mentioning

confidence: 99%

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

et al. 2008

View full text Add to dashboard Cite

The objective of this study is to determine the progress and trends in the treatment and survival of women with early-stage (I -II) epithelial ovarian cancer. Data were obtained from the SEER database between 1988 and 2001. Kaplan -Meier and Cox regressions methods were employed for statistical analyses. Of the 8372 patients, the median age was 57 years (range: 12 -99 years). A total of 6152 patients (73.4%) presented with stage I and 2220 (26.5%) with stage II disease. Over the periods 1988 -1992, 1993 -1997, and 1998 -2001, 3-year disease-specific survivals increased from 86.1 to 87.2 to 88.8% (P ¼ 0.076). The number of patients that underwent lymphadenectomy has increased significantly from 26.2 to 38.7 to 54.2% over the study period (Po0.001). Of those patients who underwent staging procedures with lymphadenectomy, there was no improvement in survival over the three study periods (from 93.2 to 93.5 to 93.1%; P ¼ 0.978). On multivariate analysis, younger age, nonclear cell histology, earlier stage, lower grade, surgery, and lymphadenectomy were significant independent prognostic factors for improved survival. After adjusting for surgical staging with lymphadenectomy, the year of diagnosis was no longer an important prognostic factor. In conclusion, the use of lymphadenectomy during surgery for early-stage ovarian cancer has doubled over the last 14 years. The marginal improvement in survival demonstrated over time is potentially attributed to the increased use of staging procedures with lymphadenectomy.

show abstract

Carcinoma of the Ovary

Cited by 991 publications

References 0 publications

An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer

An apoptotic molecular network identified by microarray: On the TRAIL to new insights in epithelial ovarian cancer

Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Müllerian system origin?

The treatment and outcomes of early-stage epithelial ovarian cancer: have we made any progress?

Contact Info

Product

Resources

About